Prime Medicine, Inc.PRMENASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank86
3Y CAGR-11.7%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-11.7%/yr
Quarterly compound
Percentile
P86
Within normal range
vs 3Y Ago
0.7x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 31.49% |
| Q3 2025 | -14.55% |
| Q2 2025 | -1.26% |
| Q1 2025 | 7.99% |
| Q4 2024 | -12.77% |
| Q3 2024 | 11.90% |
| Q2 2024 | 12.93% |
| Q1 2024 | -14.72% |
| Q4 2023 | 24.69% |
| Q3 2023 | -1.55% |
| Q2 2023 | 16.44% |
| Q1 2023 | -4.90% |
| Q4 2022 | 45.66% |
| Q3 2022 | -10.28% |
| Q2 2022 | 18.39% |
| Q1 2022 | -13.44% |
| Q4 2021 | 137.43% |
| Q3 2021 | 161.17% |
| Q2 2021 | -16.56% |
| Q1 2021 | 3.81% |
| Q4 2020 | 0.00% |
| Q4 2019 | 0.00% |